Drug Trial Radar · NCT05885464
A Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL)
Last checked: Nov 19, 2026Latest source record: Jan 13, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
5
Actual
Start
May 25, 2023
Primary completion
Dec 2026
Study completion Dec 2026
Sponsor
- Lead sponsor
- Beam Therapeutics Inc.Industry
- Sponsor type
- Industry
- First posted
- Jun 2, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 1/2, multicenter, open-label study to evaluate the safety and efficacy of BEAM-201 in patients with relapsed/refractory T-ALL or T-LL. This study consists of Phase 1 dose-exploration cohorts, Phase 1 dose-expansion cohort(s), a Phase 1 pediatric cohort (will enroll patients ages 1 to \< 12 years), and a Phase 2 cohort.
Conditions
- Lymphoblastic Lymphoma
- T-Cell Lymphoblastic Leukemia/Lymphoma
- Lymphoblastic Leukemia
Interventions
BEAM-201Biological
A single dose of BEAM-201 administered by IV following one of two lymphodepletion regimens
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and severity of treatment-emergent adverse events (TEAEs) and treatment-related adverse events, including serious adverse events (SAEs) and dose-limiting toxicities (DLTs; in Phase 1 only)Time frame: Through study completion, an average of 25 months
- Overall response rate as defined as proportion of T-ALL patients achieving complete response (CR) or complete response with incomplete hematologic recovery (CRi) or T-LL patients achieving CR or PR at any point after BEAM-201 infusionTime frame: From treatment with BEAM-201 through study completion
Locations
10 sites in 1 country. Site status is shown where the registry gives one.
Stanford University School of Medicine
Stanford, California
Colorado Blood Cancer Institute
Denver, Colorado
University of Chicago
Chicago, Illinois
The University of Kansas Cancer Center
Fairway, Kansas
Dana Farber and Boston Children's Hospital
Boston, Massachusetts
Cleveland Clinic- Taussig Cancer Center
Cleveland, Ohio
OHSU Knight Cancer Institute Hematology Oncology
Portland, Oregon
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania
Sarah Cannon- TriStar Bone Marrow Transplant
Nashville, Tennessee
Methodist Hospital - Texas Transplant Institute
San Antonio, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.